Clinical Trial

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to see if alectinib in combination with duvelisib is a safe and effective time-limited treatment for people with relapsed or refractory ALK+ anaplastic large cell lymphoma (ALCL). The researchers will test different doses of the study drugs to find the highest doses that cause few or mild side effects in participants. Once they find this dose combination, they will test it in a new group of participants to learn how long the effect of the combination lasts after the end of treatment
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-23; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT07001384
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Genentech, Inc., Secura Bio, Inc.
Conditions Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Enrollment 30 participants
Start Date 2025-08-08
Primary Completion 2031-08-08 (estimated)
Study Completion 2031-08-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-26